Twist Bioscience Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Twist Bioscience Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($77.67M) | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | ($208.73M) | Nov 17, 2025 |
| FY2025 | Sep 30, 2023 | ($204.62M) | Nov 17, 2025 |
| FY2024 | Sep 30, 2022 | ($217.86M) | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | ($152.10M) | Nov 21, 2023 |
| FY2022 | Sep 30, 2020 | ($139.93M) | Jun 5, 2023 |
| FY2021 | Sep 30, 2019 | ($107.67M) | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | ($71.24M) | Nov 27, 2020 |
| FY2019 | Sep 30, 2017 | ($59.31M) | Dec 13, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($136.26M) | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | ($220.83M) | Nov 17, 2025 |
| FY2025 | Sep 30, 2023 | ($217.16M) | Nov 17, 2025 |
| FY2024 | Sep 30, 2022 | ($234.78M) | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | ($152.73M) | Nov 21, 2023 |
| FY2022 | Sep 30, 2020 | ($140.08M) | Jun 5, 2023 |
| FY2021 | Sep 30, 2019 | ($108.85M) | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | ($70.56M) | Nov 27, 2020 |
| FY2019 | Sep 30, 2017 | ($58.48M) | Dec 13, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $80.29M | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | $90.85M | Nov 17, 2025 |
| FY2025 | Sep 30, 2023 | $106.89M | Nov 17, 2025 |
| FY2024 | Sep 30, 2022 | $120.31M | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $69.07M | Nov 21, 2023 |
| FY2022 | Sep 30, 2020 | $43.01M | Jun 5, 2023 |
| FY2021 | Sep 30, 2019 | $35.68M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $20.35M | Nov 27, 2020 |
| FY2019 | Sep 30, 2017 | $19.17M | Dec 13, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $246.98M | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | $218.40M | Nov 17, 2025 |
| FY2025 | Sep 30, 2023 | $189.74M | Nov 17, 2025 |
| FY2024 | Sep 30, 2022 | $212.95M | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $135.90M | Nov 21, 2023 |
| FY2022 | Sep 30, 2020 | $103.27M | Jun 5, 2023 |
| FY2021 | Sep 30, 2019 | $80.13M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $43.45M | Nov 27, 2020 |
| FY2019 | Sep 30, 2017 | $26.06M | Dec 13, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($47.63M) | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | ($64.09M) | Nov 17, 2025 |
| FY2025 | Sep 30, 2023 | ($142.47M) | Nov 17, 2025 |
| FY2024 | Sep 30, 2022 | ($124.39M) | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | ($112.24M) | Nov 21, 2023 |
| FY2022 | Sep 30, 2020 | ($142.26M) | Jun 5, 2023 |
| FY2021 | Sep 30, 2019 | ($87.94M) | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | ($66.16M) | Nov 27, 2020 |
| FY2019 | Sep 30, 2017 | ($51.30M) | Dec 13, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $28.00M | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | $5.08M | Nov 17, 2025 |
| FY2025 | Sep 30, 2023 | $27.78M | Nov 17, 2025 |
| FY2024 | Sep 30, 2022 | $101.86M | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $27.06M | Nov 21, 2023 |
| FY2022 | Sep 30, 2020 | $9.87M | Jun 5, 2023 |
| FY2021 | Sep 30, 2019 | $14.76M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $3.69M | Nov 27, 2020 |
| FY2019 | Sep 30, 2017 | $6.59M | Dec 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $641.86M | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | $614.32M | Nov 17, 2025 |
| FY2024 | Sep 30, 2023 | $776.40M | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | $961.38M | Nov 21, 2023 |
| FY2022 | Sep 30, 2021 | $702.10M | Jun 5, 2023 |
| FY2021 | Sep 30, 2020 | $398.88M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $186.99M | Nov 27, 2020 |
| FY2019 | Sep 30, 2018 | $115.79M | Dec 13, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $168.90M | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | $141.63M | Nov 17, 2025 |
| FY2024 | Sep 30, 2023 | $152.97M | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | $171.99M | Nov 21, 2023 |
| FY2022 | Sep 30, 2021 | $121.28M | Jun 5, 2023 |
| FY2021 | Sep 30, 2020 | $62.62M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $34.91M | Nov 27, 2020 |
| FY2019 | Sep 30, 2018 | $26.73M | Dec 13, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $472.96M | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | $472.69M | Nov 17, 2025 |
| FY2025 | Sep 30, 2023 | $623.43M | Nov 17, 2025 |
| FY2025 | Sep 30, 2022 | $789.39M | Nov 17, 2025 |
| FY2024 | Sep 30, 2021 | $580.82M | Nov 18, 2024 |
| FY2023 | Sep 30, 2020 | $336.26M | Nov 21, 2023 |
| FY2022 | Sep 30, 2019 | $152.08M | Jun 5, 2023 |
| FY2021 | Sep 30, 2018 | ($201.42M) | Nov 23, 2021 |
| FY2020 | Sep 30, 2017 | ($133.36M) | Nov 27, 2020 |
| FY2019 | Sep 30, 2016 | ($76.61M) | Dec 13, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $82.20M | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | $85.81M | Nov 17, 2025 |
| FY2025 | Sep 30, 2023 | $85.81M | Nov 17, 2025 |
| FY2024 | Sep 30, 2022 | $85.81M | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | $22.43M | Nov 21, 2023 |
| FY2022 | Sep 30, 2020 | $1.14M | Jun 5, 2023 |
| FY2020 | Sep 30, 2019 | $1.14M | Nov 27, 2020 |
| FY2019 | Sep 30, 2018 | $1.14M | Dec 13, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($1.32B) | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | ($1.24B) | Nov 17, 2025 |
| FY2024 | Sep 30, 2023 | ($1.03B) | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | ($828.42M) | Nov 21, 2023 |
| FY2022 | Sep 30, 2021 | ($610.55M) | Jun 5, 2023 |
| FY2021 | Sep 30, 2020 | ($458.46M) | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | ($318.52M) | Nov 27, 2020 |
| FY2019 | Sep 30, 2018 | ($210.86M) | Dec 13, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $183.05M | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | $226.32M | Nov 17, 2025 |
| FY2024 | Sep 30, 2023 | $286.47M | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | $378.69M | Nov 21, 2023 |
| FY2022 | Sep 30, 2021 | $465.83M | Jun 5, 2023 |
| FY2021 | Sep 30, 2020 | $93.67M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $46.74M | Nov 27, 2020 |
| FY2020 | Sep 30, 2018 | $80.76M | Nov 27, 2020 |
| FY2019 | Sep 30, 2017 | $31.23M | Dec 13, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2020 | $4.17M | Nov 27, 2020 |
| FY2019 | Sep 30, 2019 | $7.50M | Dec 13, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (1) | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | (3) | Nov 17, 2025 |
| FY2025 | Sep 30, 2023 | (3) | Nov 17, 2025 |
| FY2024 | Sep 30, 2022 | (4) | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | (3) | Nov 21, 2023 |
| FY2022 | Sep 30, 2020 | (3) | Jun 5, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (1) | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | (3) | Nov 17, 2025 |
| FY2025 | Sep 30, 2023 | (3) | Nov 17, 2025 |
| FY2024 | Sep 30, 2022 | (4) | Nov 18, 2024 |
| FY2023 | Sep 30, 2021 | (3) | Nov 21, 2023 |
| FY2022 | Sep 30, 2020 | (3) | Jun 5, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 60.63M | Nov 17, 2025 |
| FY2025 | Sep 30, 2024 | 58.88M | Nov 17, 2025 |
| FY2024 | Sep 30, 2023 | 57.56M | Nov 18, 2024 |
| FY2023 | Sep 30, 2022 | 56.52M | Nov 21, 2023 |
| FY2022 | Sep 30, 2021 | 49.50M | Jun 5, 2023 |
| FY2021 | Sep 30, 2020 | 45.08M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | 32.87M | Nov 27, 2020 |
| FY2019 | Sep 30, 2018 | 3.21M | Dec 13, 2019 |